drugset / Trial / NCT07321093
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
RandomizedParallel-groupTriple-blindTreatment
Summary
The aim of this study is to compare the efficacy, safety profile, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 and the reference drug in subjects with relapsing multiple sclerosis.
Timeline
- Start
- 2025-11-01
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCD-281 | Monoclonal antibody | 600 mg | — |
| Comparator | Ocrelizumab | Monoclonal antibody | 600 mg | — |